NFKB1 and Alzheimer disease: Indeed anti-NF-kB, anti-miRNA-34a and/or analogous pharmacological molecular strategies may be useful in the future clinical management of AD and other multi-pathway neurological diseases with an amyloidogenic component, including novel combinatorial therapeutic approaches that have not yet been considered.